Relapse Refractory Follicular Lymphoma

The augment trial was really looking at patients with relapse refractory indolent non-Hodgkin slumphoma both licular and marginal zone were included in this data set. The CR8 is 43% the 12 month PFS was 39% in this trial so further data needed I'm not sure that mose and the tusumab is the strongest by specific in the large cell space but we're just gonna have to see where this is gonna go. Next study kind of leaning into this you know Me2 clinical trial landscape in this is in relaps refractory follicular lymphoma is taking the EZH2 oral therapy tasmidostat.